SG Americas Securities LLC Boosts Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

SG Americas Securities LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 967.4% in the 4th quarter, HoldingsChannel reports. The firm owned 24,593 shares of the company’s stock after purchasing an additional 22,289 shares during the period. SG Americas Securities LLC’s holdings in Medpace were worth $8,171,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Stone House Investment Management LLC acquired a new stake in shares of Medpace during the 3rd quarter worth about $33,000. Ashton Thomas Securities LLC acquired a new position in shares of Medpace in the third quarter valued at approximately $37,000. Capital Performance Advisors LLP acquired a new stake in shares of Medpace in the 3rd quarter worth $46,000. True Wealth Design LLC boosted its holdings in Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Finally, UMB Bank n.a. raised its stake in shares of Medpace by 191.4% during the 3rd quarter. UMB Bank n.a. now owns 271 shares of the company’s stock worth $90,000 after buying an additional 178 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several research analyst reports. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Robert W. Baird upped their target price on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research note on Monday, November 25th. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and decreased their price target for the company from $420.00 to $350.00 in a report on Friday, September 27th. Truist Financial dropped their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Finally, TD Cowen decreased their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $380.56.

Medpace Trading Up 0.8 %

Shares of NASDAQ:MEDP opened at $347.90 on Friday. The firm has a market cap of $10.81 billion, a price-to-earnings ratio of 30.46, a P/E/G ratio of 1.78 and a beta of 1.36. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77. The business has a fifty day simple moving average of $339.40 and a 200 day simple moving average of $356.05.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. During the same quarter last year, the firm posted $2.22 EPS. The company’s revenue was up 8.3% on a year-over-year basis. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.